Highlights
- Multiple new data announced for RAD 301 and RAD 302 programs.
- RAD 301 and RAD 302 programs were presented at the European Molecular Imaging Meeting (EMIM).
- RAD 302 is a 177Lu-labelled peptide-based therapeutic agent and RAD 301 is a 68Ga-labelled peptide-based imaging agent.
- Both these agents target αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth.
Radiopharm Theranostics Limited (ASX: RAD) has released multiple new data for its RAD 301 and RAD 302 programs. Both programs were presented at the 2024 European Molecular Imaging Meeting (EMIM) in Portugal this week.
Over 1,000 international participants take part in the EMIM. In the event, latest developments across molecular, functional and morphological imaging are presented. The event also includes discussions around new strategies for image-guided therapies and theranostics.
The technology of RAD was featured in three presentations –
Data source: Company update
RAD shares traded at AU$0.058 apiece at the time of writing on 15 March 2024